Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq

[1]  S. Vaniawala,et al.  Development, Validation and Clinical Evaluation of a Low Cost In-House HIV-1 Drug Resistance Genotyping Assay for Indian Patients , 2014, PloS one.

[2]  R. Paredes,et al.  Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Michael S. Braverman,et al.  An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. , 2014, Journal of virological methods.

[4]  T. de Oliveira,et al.  An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings , 2014, Journal of visualized experiments : JoVE.

[5]  David L. Robertson,et al.  Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism , 2014, Antimicrobial Agents and Chemotherapy.

[6]  R. Glaubius,et al.  Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models , 2013, AIDS.

[7]  R. Westergaard,et al.  Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users , 2013, AIDS.

[8]  Richard D Moore,et al.  Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. , 2013, The Journal of clinical investigation.

[9]  Robert Glaubius,et al.  Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. , 2013, The Journal of infectious diseases.

[10]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[11]  J. Schapiro,et al.  Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. , 2013, The Journal of infectious diseases.

[12]  Alexander Schönhuth,et al.  Discovering motifs that induce sequencing errors , 2013, BMC Bioinformatics.

[13]  R. Stephens,et al.  Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA , 2013, Retrovirology.

[14]  Astrid Gall,et al.  Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes , 2012, Journal of Clinical Microbiology.

[15]  H. Swerdlow,et al.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.

[16]  S. Hammer,et al.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. O’Connor,et al.  Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance , 2012, PloS one.

[18]  T. F. Rinke de Wit,et al.  Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  T. Dallman,et al.  Performance comparison of benchtop high-throughput sequencing platforms , 2012, Nature Biotechnology.

[20]  B. Lau,et al.  HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Erin K. Rottinghaus,et al.  Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings , 2011, PloS one.

[22]  N. Galai,et al.  Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[24]  C. Delaugerre,et al.  Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen , 2011, PloS one.

[25]  S. Swindells,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2011, Journal of Family Planning and Reproductive Health Care.

[26]  P. Ghys,et al.  Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.

[27]  M. Peeters,et al.  High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity , 2011, Journal of Clinical Microbiology.

[28]  Austin L. Hughes,et al.  Whole-Genome Characterization of Human and Simian Immunodeficiency Virus Intrahost Diversity by Ultradeep Pyrosequencing , 2010, Journal of Virology.

[29]  J. Lundeberg,et al.  Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected Using Ultra-Deep Pyrosequencing , 2010, PloS one.

[30]  A. Kamali,et al.  Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. , 2010, Journal of virological methods.

[31]  N. Marlowe,et al.  Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. , 2009, AIDS Research and Human Retroviruses.

[32]  M. Ronaghi,et al.  Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.

[33]  J. Eshleman,et al.  Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. , 2006, The Journal of molecular diagnostics : JMD.

[34]  R. Shafer.  Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.

[35]  H. Schumny.  Next generation , 2005, Comput. Stand. Interfaces.

[36]  S. Galea,et al.  Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. , 2005, American journal of epidemiology.

[37]  C. Brennan,et al.  Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Diverse Human Immunodeficiency Virus Type 1 Strains , 2004, Journal of Clinical Microbiology.

[38]  A Munoz,et al.  The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods , 1991, NIDA research monograph.

[39]  L. Saravolatz,et al.  The quad pill, a once-daily combination therapy for HIV infection. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  D. Pillay,et al.  Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. , 2014, The Journal of general virology.

[41]  P. van den Eede,et al.  HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance. , 2013, Methods in molecular biology.

[42]  Bradley J. Betts,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database. , 2003, Nucleic acids research.